Introduction
It is now accepted that most cancers are a result of the dysregulation of multiple molecular pathways. This paradigm has been proven in many solid tumors with the recognition of pre-malignant lesions that frequently precede invasive cancer. Studies of solid tumors have provided insight into the sequence of molecular alterations associated with tumor progression. However, this paradigm does not immediately extend to lymphomas, due to the innate circulatory capacity of lymphocytes, rendering the concept of "benign lymphoma" more challenging. Indeed, in contrast to epithelial and mesenchymal neoplasms, classification systems have not recognized both benign and malignant lymphomas. For many indolent lymphoproliferative disorders, the clonally expanded lymphocytes do not remain localized, but disseminate based on the patterns of normal lymphocyte homing. They also are frequently responsive to immunoregulatory signals; it is only when the proliferation becomes autonomous that features of malignancy are clearly evident. Thus, these early lesions have many of the attributes of benign neoplasms.
The expansion in knowledge of disease-specific genetic and phenotypic alterations has resulted in the detection of clonal lymphoid lesions sharing genetic and/or phenotypic aberrations with well-defined neoplasms like chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), multiple myeloma (MM), follicular lymphoma (FL) and mantle cell lymphoma (MCL) without fulfilling diagnostic criteria for overt malignancy. A second group of "indolent" and indeterminate clonal lymphoid proliferations do not have a counterpart among the currently recognized subtypes of lymphoma, but appear to have a limited potential for progression. Their optimal therapeutic management has not been clear and recent data suggest that conservative management may be sufficient in most cases. Included in this group are the pediatric variants of follicular lymphoma and nodal marginal zone lymphoma, as well as breast-implant associated anaplastic large cell lymphoma (ALCL)
These observations raise important practical and theoretical questions, some of which were addressed at a recent workshop on this subject. 1 What is the definition of "malignant lymphoma" in 2014, since neither monoclonality nor genetic aberrations equate with malignancy based on current knowledge? Clonal populations of B and T lymphocytes have been identified in many reactive or infectious disorders, and many lymphoma-or leukemia-associated translocations have been identified in the peripheral blood of healthy individuals. 2 In this review, we summarize the diagnostic criteria, recent advances in predicting progression and current recommendations for management of the more recently recognized early or indeterminate clonal lymphoid lesions of B-cell, T-cell and NK-cell derivation (Table 1 ). An understanding of these indolent and sometimes self-limited proliferations is critical to determine the appropriate clinical management. We have omitted discussion of lymphomatoid papulosis and the spectrum of primary cutaneous CD30-positive T-cell lymphoproliferative disorders as this topic has been covered extensively in the literature. 3 Similarly, in the interest of space, we will not discuss lymphoproliferative disorders secondary to viral transformation. 4 Diagnostic criteria for some of these early lesions were incorporated into the 2008 World Health Organization (WHO) classification of lym-
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Karthik A. Ganapathi, 1 Stefania Pittaluga, 1 Oreofe O. Odejide, 2 Arnold S. Freedman, 2 and Elaine S. Jaffe ated with its malignant counterpart, and nearly always precedes plasma cell myeloma. 6, 7 The diagnostic criteria for MGUS are: serum M-protein less than 3 g/dL, BM monoclonal plasma cells less than 10%, no evidence of myeloma, lymphoproliferative disorders or amyloidosis. 8 The incidence of MGUS increases with age and has a small but definitive risk of progression to myeloma at an annual rate of 1%. 9 Multiple factors affect the progression of MGUS to myeloma. 10 IgM MGUS should be distinguished from MGUS associated with other heavy chain classes, and is closely tied to Waldenstrom's macroglobulinemia.
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MGUS and myeloma share cytogenetic alterations including major translocations involving the IGH gene; an increased incidence of chromosome 13 deletions is seen in myeloma in a background of specific cytogenetic aberrations suggesting a role in disease evolution. 12, 13 Single nucleotide polymorphism (SNP) based-array studies have shown increasing copy number abnormalities during progression from MGUS to myeloma.
14 Recent studies have emphasized the significance of genetic alterations, suggesting that genetic profiling may prove to be an important tool in MGUS risk-stratification, 15 and support the view that progression of MGUS to myeloma results from the selection and expansion of multiple aberrant clones rather than a linear step-wise acquisition of specific genetic abnormalities. 16 The current management of MGUS involves careful monitoring and no therapeutic intervention unless the patient is on a clinical trial. 17 The IMWG 2010 guidelines recommend MGUS risk-stratification based on the Mayo scheme. Low-risk MGUS patients should be followed up with serum electrophoresis six months after diagnosis and subsequently every 2-3 years, or when symptomatic. Intermediate-risk and high-risk MGUS patients should undergo a base-line bone marrow examination including cytogenetics and skeletal survey, and should be followed up with serum studies twice in the first year and annually thereafter.
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Monoclonal B-cell lymphocytosis
The widespread use of flow cytometric analysis has led to the detection of low levels of clonal B-cell populations with chronic lymphocytic leukemia (CLL)-like immunophenotype in asymptomatic individuals with normal peripheral blood counts. 19 MBL is defined as the presence of a circulating monoclonal B-cell population below 5 x 10 9 /L, persisting for at least three months, in otherwise asymptomatic individuals. 20 Higher sensitivity flow cytometric analyses have shown an age-dependent increase in the prevalence of CLL-like B cells in individuals without lymphocytosis suggesting that the reported prevalence of MBL is dependent on diagnostic sensitivity. 21 Supporting this view, MBL has been diagnosed in normal healthy blood donors, over 45 years of age, at higher levels than previously reported. 22 Based on clonal B-cell counts and clinical significance, MBL is now subdivided into highcount MBL (0.5-5.0 x 10 9 /L) and low-count MBL (< 0.1 x 10 9 /L). 23 High-count MBL has the highest prevalence amongst first-degree relatives of patients with CLL 21 and, unlike low-count MBL, has IGHV mutations with a repertoire similar to CLL suggesting a biological relationship. 24, 25 However, both high-count and low-count MBL show CLL-related cytogenetic alterations including del13q, +12 and del17p, albeit at lower levels, suggesting that these 
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changes occur early in clonal evolution and are not prognostically significant in the absence of B-cell lymphocytosis. 26 High-count MBL progresses to CLL at an annual rate of 1-2% with the clonal B-cell count at presentation being the biggest risk factor. CD38 expression, IGHV mutation status and cytogenetic abnormalities were not significant risk factors on multivariate analysis, 24, 27 although one study showed +12 or del17p as predictors of survival. 28 The presence of palpable lymphadenopathy, organomegaly and/or bone marrow infiltration (> 30% of nucleated cells) fulfills the IWCLL criteria for CLL, even in the absence of clonal lymphocytosis 29 while the WHO criterion for CLL/SLL is the presence of any extramedullary involvement. However, a recent study suggested that limited nodal involvement, usually discovered incidentally, was still compatible with a diagnosis of MBL. 30 Risk factors for progression included lymphadenopathy greater than 1.5 cm by imaging and the presence of proliferation centers on histology. Bone marrow biopsies in patients with MBL have shown patchy interstitial lymphoid infiltrates indistinguishable from low-level involvement by CLL and a diagnosis of CLL should not be made on this evidence alone without supporting clinical information. 31 Further prospective studies are necessary to refine diagnostic criteria for tissue involvement with MBL.
Current recommendations for management of CLL-like MBL include yearly monitoring with intervention if clini-
haematologica | 2014; 99(9) cally indicated. Low-count MBL, based on current data, is unlikely to progress to CLL and does not warrant clinical monitoring. 23 MBL with an atypical CLL-like phenotype (CD5 + , bright CD20, CD23-) could represent an early leukemic manifestation of mantle cell lymphoma and a thorough staging workup including FISH testing for t (11;14) translocation is recommended. MBL with an atypical CLL-or non CLL-immunophenotype is rare and occurs in 1-2.5% of the general population. 32 These atypical clones can be transient and may be detected in patients with advanced HCV infection, possibly indicative of reactive clonal B-cell expansions. 33 Current guidelines recommend that patients with non-CLL-like MBL undergo a base-line evaluation to rule out a lymphoproliferative disorder, with follow up as clinically indicated. 21 However, a retrospective study of individuals with circulating B-cell clones consistent with a marginal zone phenotype (non-CLL-type MBL) showed a low rate of progression to lymphoma, indicating that these may also represent indolent proliferations not warranting aggressive intervention in the absence of symptoms.
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Follicular lymphoma in situ/follicular lymphoma-like cells of undetermined significance
Follicular lymphoma in situ (FLIS) was initially described as the localization of atypical B cells with strong expression of CD10 and BCL-2 in the germinal centers of reactive-appearing lymph nodes. 35 These cells have the t(14;18)(IgH-BCL2) translocation, seen in approximately 85% of overt low-grade follicular lymphoma (FL). Since the majority of patients with FLIS do not develop overt lymphoma and specific risk factors for disease progression are currently unknown, the alternate term "follicular lymphoma-like B-cells of undetermined significance" (FLBUS) was recently proposed. 1 Neither term is entirely satisfactory. "FLIS" might imply an expected risk for progression in most patients, not currently thought to be the case, 36 and "FLBUS" might lead to patient anxiety for a lesion now thought to have minimal, not undetermined, clinical significance, if other clinical evidence for lymphoma is lacking. The 4 th edition of the WHO classification is currently under revision, and alternative terms will be considered. The incidence of FLIS/FLBUS in reactive lymphoid tissue is low (2-3%) 35, 37 and only diagnosed with the aid of immunohistochemistry. The lymph node architecture is intact, with reactive appearing follicles, intact mantle zones and sharply defined germinal centers. The atypical cells resemble centrocytes and show molecular and immunophenotypic evidence of the BCL2 translocation. While one study found a correlation between the number of follicles involved by FLIS/FLBUS and the risk of subsequent lymphoma, 38 two other studies did not find the degree of involvement predictive of concurrent/subsequent lymphoma. 36, 39 FLIS/FLBUS must be differentiated from partial involvement by low-grade follicular lymphoma (PFL), which usually shows partially effaced nodal architecture with enlarged, crowded follicles and attenuated mantle zones. 
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The atypical cells are a mixture of centrocytes and centroblasts, show variable intensity for CD10, BCL-2 and may extend beyond the germinal centers. 36 This distinction is clinically relevant as PFL is more likely to be associated with or progress to overt FL.
Low numbers of clonal B cells with the BCL2 translocation (follicular lymphoma-like B cells, FLLBC) may be detected in benign lymphoid tissue and peripheral blood of healthy subjects, a subject recently reviewed in detail by Mamessier et al. 40 FLLBC show preferential homing to the germinal centers of reactive lymph nodes and are nonproliferative. 41 Functionally, and in terms of risk, FLLBC in the blood of healthy individuals, and FLIS/FLBUS as detected histologically appear to be comparable. The higher incidence of circulating B cells with t(14;18) translocation in healthy subjects, compared to FLIS/FLBUS and the low rate of progression of FLIS/FLBUS, compared to PFL, to overt FL suggests these entities lie along a spectrum, and accumulate genetic alterations at every stage. Two recent high-resolution array CGH studies of FLIS/FLBUS identified a paucity of genetic aberrations in comparison with FL, supporting the conclusion that these lesions are at a very early stage of evolution, and do not represent merely seeding of germinal centers by lymphoma at a distant site. 42, 43 Of note, evidence for EZH2 mutations, thought to occur early in follicular lymphomagenesis, were found in both reports. Duodenal follicular lymphoma (DFL) showed a similar low level of aberrations, while PFL appeared to represent an intermediate stage of evolution. 42 The specific factors that determine progression of FLIS/FLBUS to FL still have to be clarified, but if there is no other evidence of disease at diagnosis, the risk of progression is low (less than 10%). 36 However, analogous to MGUS and MBL, retrospective review of "reactive" lymph nodes biopsied prior to a FL diagnosis has shown FLIS/FLBUS in a subset. 36, 39 In approximately 15-20% of cases FLIS/FLBUS has been diagnosed in a lymph node involved by another B-cell lymphoma (Figure 1) . 36, 38, 39 This finding might suggest that patients with FLIS/FLBUS are at increased risk, or it might be coincidental, due to the panel of immunostains routinely used to evaluate such biopsies.
Until more accurate predictive biomarkers are available, all patients with a diagnosis of FLIS/FLBUS should undergo a staging workup, including whole body imaging and bone marrow biopsy to rule out concurrent lymphoma. In the absence of overt lymphoma, conservative management is recommended, even in the presence of multi-focal FLIS/FLBUS and/or circulating FL-like cells identified by flow cytometry. 44 A recent study has shown that patients who developed FL had a higher number of circulating cells with the t(14;18) translocation compared with controls, identified up to 15 years preceding the diagnosis. 45 Thus, monitoring the level of FLLBC in the peripheral blood might provide useful information regarding the subsequent risk of FL.
Primary duodenal follicular lymphoma
Primary gastrointestinal (GI) follicular lymphoma is rare and most often involves the duodenum. [46] [47] [48] In view of its unique clinicopathological features, primary intestinal (duodenal) follicular lymphoma (DFL) was recognized as a separate variant of FL in the 2008 World Health Organization classification. 5 It shares many features with FLIS/FLBUS in terms of its usually benign natural history.
Most cases are diagnosed on endoscopy, often performed for reasons unrelated to the subsequent FL diagnosis. Endoscopic features include solitary or multiple polyps, mucosal nodularity or plaques. Multifocal involvement is typically seen, with lesions seen in the descending part of the duodenum, jejunum and rarely involving the ileum and limited to the mucosa/submucosa on imaging. 47 The risk of progression and dissemination is very low (<5%). 47 Histologically, the atypical follicles are limited to the mucosa and submucosa, are well circumscribed, and composed almost entirely of centrocytes. The atypical B cells infiltrate the lamina propria and distort the villi. Molecular testing for IGH clonality or cytogenetics/ FISH analysis for t(14;18)(IGH-BCL2) is positive in the majority of cases. 47 Studies have shown disrupted follicular dendritic cell (FDC) meshworks and lack of activation-induced deaminase (AID) expression in DFL, in contrast to nodal FL. The increased incidence of Ig VH4 and VH5 chains in DFL suggests an AID-and FDC-independent mechanism of somatic mutation, 49 and the expression of α4b7 integrin, a mucosal homing integrin, and IgA, in DFL, supports a mucosal origin and local antigen-driven clonal expansion of B cells. 50 High resolution array CGH analysis has shown that DFL shares genomic aberrations with FLIS and PFL suggesting common pathways of origin. 42 However, unlike in PFL, a large fraction of these alterations were not shared with FL. In the context of reduced AID expression in DFL, these aberrations could have occurred before downregulation of AID or independent of it. The lack of AID could also explain a reduced capacity for ongoing mutations and limited disease presentation. 40 DFL has an indolent clinical course, with more than 95% of patients showing no systemic involvement or progression after a median follow up of 77 months. There were no significant differences in survival or time to progression between treated and untreated patients, supporting the view that in the absence of disease progression, judicious follow up and observation is preferred to aggressive therapy. 47 When treated, very high CR rates were obtained with either radiation or rituximab, or chemotherapy with or without radiation. 47 DFL should be distinguished from typical FL, which also can present with intestinal disease. 51 In such cases, mesenteric lymph node involvement is often present, and the mass may impinge on the lumen causing intestinal obstruction.
Mantle cell lymphoma in situ/mantle cell lymphoma-like B cells of undetermined significance
Analogous to FLIS/FLBUS, colonization of the mantle cuffs of reactive follicles by cyclin D1-positive B cells, diagnosed incidentally has been termed MCLIS or MCLBUS. 1, 52 The positive cells carry the t(11;14)(CCND1-IGH) characteristic of mantle cell lymphoma (MCL). The same challenging issues of terminology that pertain to FLIS/FLBUS apply here as well.
MCLIS/MCLBUS is a rare incidental finding in lymph nodes or extranodal lymphoid tissue and is seen in a background of preserved architecture and reactive hyperplasia. The mantle zones are not expanded and the atypical cyclin D1-positive cells are seen predominantly within the inner layers of the mantle cuffs. These cases must be differentiated from early/partial involvement with overt MCL with a mantle zone growth pattern ( Figure 1C and  D) . This distinction is important as partial MCL is more likely to progress or co-exist with advanced disease.
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Sox11 expression was present in less than 50% of MCLIS/MCLBUS cases in one study 52 while all MCLIS/MCLBUS cases submitted to a workshop were positive. 1 Whether Sox11 may be useful in predicting the risk of progression will require additional prospective studies.
MCLIS/MCLBUS is less common than FLIS in unselected lymph node biopsies, 53 and like FLIS/FLBUS, routine screening of lymphoid tissue for MCLIS/MCLBUS is not warranted. Interestingly, some cases have been detected retrospectively through examination of lymph nodes biopsied prior to a subsequent diagnosis of MCL, suggesting that, like in FLIS/FLBUS, the neoplastic clone may be present years earlier. 52 The CCND1-IGH translocation is likely an early event in mantle cell lymphomagenesis, supported by recent studies showing circulating B cells with this translocation in the peripheral blood of healthy subjects. Although MCL-like B cells are seen at a significantly lower frequency than FLLBC, these clones can also persist for several years. 54 Interestingly, MCLIS and FLIS have been detected concurrently in some cases, 55 possibly suggesting similar mechanisms of molecular pathogenesis. 56 Current management recommendations for MCLIS/MCLBUS include whole body imaging and unilateral bone marrow biopsy (if indicated) to rule out a concomitant overt lymphoma. In the absence of overt disease, no treatment is required and careful follow up is advised. 44 The natural history of MCLIS/MCLBUS is unknown.
Pediatric variant of follicular lymphoma/pediatric-type follicular lymphoma
While usual FL is almost never seen in patients under 18 years of age, the WHO classification recognized a distinctive variant of FL mainly seen in the pediatric and young adult age group. 57, 58 Known as the pediatric variant or pediatric type of FL (PTFL), it differs from the adult counterpart morphologically, immunophenotypically, and genetically. 59, 60 It presents predominantly in young males, most often as isolated cervical lymphadenopathy. The tumor lacks the characteristic t(14;18)(IGH-BCL2) translocation, and is most often negative for BCL-2 protein as well. Lymph node architecture is partially or totally effaced by expansile, serpiginous follicles with a prominent "starry sky" appearance. The atypical follicles are composed of medium-sized to large blastoid cells, rather than typical centroblasts (Figure 2A-D) . 57 However, grading as performed for usual FL is not required. The cells express BCL6 and CD10. However, BCL6 and MYC aberrations typically associated with aggressive B-cell lymphomas are absent. 57, 58, 61, 62 Overlap with florid follicular hyperplasia remains a practical and theoretical problem, as most PTFL lack specific genetic aberrations, and whether some of these cases may represent limited clonal expansions in florid follicular hyperplasia is still a subject of debate. 63 Nodal PTFL is an indolent disease with a very good prognosis. Most patients present with limited stage disease and have an excellent response to surgery alone or surgery followed by chemotherapy or radiotherapy. 57, 58, 61, 64, 65 Adverse risk factors of conventional FL, including high cytologic grade, absence of BCL2 rearrangements, and high proliferative index, do not have an impact on prognosis in PTFL, suggesting that it is biologically and clinically distinct from conventional FL. While typically seen in young patients, cases with similar morphology and phenotype are also seen in adults. 57, 58 Thus, the term "pediatric-type follicular lymphoma" was proposed to emphasize this behavior and ensure conservative management. 58 Pediatric lymphomas with a follicular component that likely require more aggressive management include those with identifiable chromosomal aberrations. 62 Some of these will show association with diffuse large B-cell lymphoma. Another subset, often involving Waldeyer's ring, is associated with translocations involving IRF4 and high expression of MUM1. 66 B-cell lymphomas with IRF4 aberrations lack the distinctive features of the PTFL and are thought to represent a separate disease entity. 57 
Pediatric variant of nodal marginal zone lymphoma
Nodal marginal zone lymphoma, while uncommon in the pediatric population, shows characteristic clinical and pathological features. Similar to PTFL, pediatric NMZL is more common in males, especially in patients under 18 years of age, with a M:F ratio of 20:1. 67 It presents as asymptomatic isolated lymphadenopathy, commonly in the head and neck region. Morphologically, residual follicles are often present, and show fragmentation with thin mantle zones ( Figure 2E-I) . Clonality can usually be demonstrated by flow cytometry, immunohistochemistry or molecular analysis. 67, 68 Approximately 20% of pediatric NMZL have cytogenetic aberrations. Trisomies of chromosomes 3 and 18 are the most common 68 and are also encountered in MZL in adults. 69 Pediatric NMZL and PTFL show overlapping pathological features, in addition to marked clinical similarities. 57, 58, 67 These observations suggest a close relationship, and possibly a similar pathogenesis. Whether these are different faces of the same antigen driven process remains to be explored. Both should be distinguished from atypical marginal hyperplasia of the tonsils and appendix occurring in children with lambda light chain restriction, but negative for clonality by molecular studies. 70 Pediatric NMZL is an indolent process with most patients presenting with localized, low-stage disease and no documented reports of large cell transformation. Surgical excision is curative in most patients with no reports of relapse. 67 Like PTFL, pediatric NMZL may be seen in adults. 71 Recognition of this unique, indolent variant can prevent misdiagnosis and overtreatment.
Primary cutaneous lymphomas of low malignant potential
The skin is the site of involvement of a group of primary cutaneous lymphomas or lymphoproliferative disorders that are clonal at the molecular level but have a very indolent clinical course, with a low risk of spread beyond the skin. They can be managed with local approaches in nearly all cases, and it could be questioned whether they properly belong among the group of "malignant lymphomas". They will briefly be reviewed as a group, given the common issues of clinical management.
Primary cutaneous follicle center lymphoma
Primary cutaneous follicle center lymphoma (PCFCL) comprises approximately 10% of all cutaneous lymphomas and is the most common cutaneous B-cell lymphoma. It was recognized as a separate entity in the 2008 WHO classification. It usually presents as solitary or Early events in lymphomagenesis haematologica | 2014; 99 (9) grouped plaques in the head and neck or trunk, sometimes with erythematous papules and nodules. Involvement of the extremities is rare. PCFCL can have a nodular, nodular and diffuse or entirely diffuse pattern involving the dermis and subcutaneous tissue. Centrocytes, which may be large, often predominate, and grading is not required. BCL2 expression, if positive, is weak and variable 72, 73 but the t(14;18)(IGH-BCL2) translocation is usually negative, and if present, should raise concern for secondary cutaneous involvement. 74 Clonal immunoglobulin gene rearrangements can be detected in more than 90% of cases. 75, 76 PCFCL has an excellent prognosis with more than 95% 5-year survival. 73, 77 Small, well-demarcated solitary lesions are treated with surgical excision or radiation therapy with 40-70% of patients having cutaneous relapses. 78 Patients with few scattered lesions are treated with both radiotherapy of all visible skin lesions and a "waitand-watch" approach. Patients with extensive skin lesions are treated with systemic rituximab (with a high rate of relapse in skin, although PFS is a median of 40 months) or combination chemoimmunotherapy considered in rare circumstances. Cutaneous relapses, occurring in nearly 30% of patients, do not signify a worse prognosis and a similar approach for management is recommended. In one study, PCFCL arising in the leg behaved more aggressively, suggesting the need for more aggressive therapy in this subset. 73 A biological basis for this observation has not been provided.
Primary cutaneous marginal zone lymphoma
Primary cutaneous marginal zone lymphoma (PCMZL) is considered a unique entity in the WHO-EORTC classification. 79 It is a rare B-cell neoplasm comprising less than 10% of all cutaneous lymphomas. Borrelia burgdorferi DNA has been identified in a minority of cases from endemic areas, suggesting a possible etiology, analogous to H.pylori infection and gastric MALT lymphomas. 80 However, other studies, including those from regions where Borrelia is common, have not confirmed this finding. 81, 82 PCMZL presents as solitary or multiple papules/nodules most often in the upper extremities, and is usually not seen in the head and neck. Plasmacytoid differentiation is common. However, in contrast to MZL in most other sites, the cells show evidence of class switching, and express IgG rather than IgM. 83 MALT-lymphoma associated translocations have not been described. 81, 84, 85 but clonality can usually be shown by PCR. 75, 76 PCMZL is an indolent disease with a 5-year disease-specific survival of over 95%. 77 Staging procedures with whole body imaging are recommended to rule out cutaneous involvement by MZL at other sites. Solitary lesions are excised with a "watch and wait" approach. Radiotherapy is effective for grouped lesions with intralesional steroids also being highly effective. 78 Cutaneous relapses are treated similarly and do not lead to a worse prognosis.
Primary cutaneous small/medium CD4-positive T-cell lymphoma
Primary cutaneous small/medium CD4-positive T-cell lymphoma (PCSMTCL) was a provisional entity in the WHO 2008 Classification. Clinically, these lesions are predominantly solitary, presenting in the head and neck area with rare lesions in the trunk and extremities. Histologically, nodular lymphoid infiltrates composed of small/medium cells with irregular, pleomorphic nuclei are seen in the dermis and subcutis without epidermotropism ( Figure 3A-C) . [86] [87] [88] The T cells have a follicular T-helper phenotype and a prominent interspersed B-cell population is seen. 87 Molecular analysis shows clonal T-cell receptor gene (TCRG) rearrangement in the majority of cases. 67, 68 The majority of PCSMTCL have shown an indolent clinical course. Systemic involvement has only been reported in one series, in a subset of patients with large tumors/nodules, which might represent a different disease. 89 Prognosis is generally favorable with long-term follow-up data from a subset of patients in the largest series reported showing no deaths or disseminated disease. Although therapy for PCSMTCL is not well defined, surgical excision or radiotherapy has resulted in durable remissions in patients with localized disease. We and others prefer the term "primary cutaneous small/medium CD4-positive lymphoproliferative disorder" instead of lymphoma, to prevent unnecessary aggressive therapy. 88 
Indolent CD8-positive lymphoid proliferation of the skin
Indolent CD8-positive lymphoid proliferation of the skin was described initially as a solitary nodule of the ear 90, 91 but is now known to occur at other anatomic sites, 92 including the distal extremities. 93 Histology typically shows a non-epidermotropic, dense dermal lymphoid infiltrate composed of medium-sized atypical CD8 + T cells positive for TIA-1, but negative for Granzyme B ( Figure  3D-F) . T-cell clonality has been demonstrated in most cases. 90, 91 Initial evidence supports an indolent behavior with localized disease, and good response to surgery and radiotherapy. Rare patients have had persistent disease or local relapse but no deaths have been reported. 92 This entity must be differentiated from primary cutaneous aggressive epidermotropic CD8-positive cytotoxic T-cell lymphoma and primary cutaneous γδ T-cell lymphoma (PCGD-TCL). The latter entities present with localized or diffuse skin lesions with systemic dissemination and an aggressive clinical course.
Indolent T-cell lymphoproliferative disorders of the gastrointestinal tract
Primary T-cell lymphomas of the GI tract are rare and include enteropathy-associated T-cell lymphomas (EATL, type I and II), extranodal NK/T-cell lymphomas, nasal type and peripheral T-cell lymphomas, not otherwise specified (PTCL, NOS). All of these variants have an aggressive clinical course and poor prognosis. However, previously reported isolated case reports suggested that indolent GI T-cell lymphomas (Indolent T-LPD) might exist. [94] [95] [96] Two recent studies have reported clonal T-cell proliferations of the GI tract with an indolent clinical course. 97, 98 In both reports, the patients had GI symptoms suggesting either inflammatory bowel disease or celiac disease, but without response to a gluten free diet. Endoscopy revealed multiple sites of involvement, including oral cavity, esophagus, stomach, small bowel and colon. The lesions ranged from thickened mucosal folds, irregular appearing mucosa, friable erythematous mucosa or polyps. Imaging studies showed lesions limited to the GI tract.
Histologically, the lamina propria was expanded by a dense, non-destructive lymphoid infiltrate composed of small mature appearing lymphocytes. While mucosal glands were displaced by the infiltrate, epitheliotropism was not identified (Figure 4A-C) . Small bowel villous blunting was not identified in the patients reported by Perry et al. 98 whereas the presence of villous atrophy had suggested a diagnosis of celiac disease in the other report. 97 The infiltrating cells were αb T cells in all cases studied, with a very low proliferative rate. Interestingly, there has not been a consistent phenotype, with both CD4-and CD8-expressing cases identified. However, molecular analysis showed a clonal TCRG rearrangement in all. STAT3 SH2 domain mutations, recently described in T-cell large granular lymphocytic leukemia and chronic NK-lymphoproliferative disorders, 99, 100 were not identified in the 5 cases tested. 98 Six out of the 10 cases reported by Perry et al. were initially diagnosed as PTCL and patients underwent chemotherapy, but with no improvement. 98 Four patients were observed without therapy. Most patients had persistent disease without progression or dissemination for up to 14 years. However, one case that was double-negative for CD4 and CD8 progressed with involvement of the liver (AM Perry et al., 2013, personal communication) , and one case reported by Margolskee et al. underwent transformation to an intestinal large cell lymphoma with CD30 and cytotoxic marker expression. 97 Correlation of clinical history, endoscopic findings, histological features and awareness of these indolent lesions are important to avoid misdiagnosis as PTCL and unwarranted aggressive therapy. Similarities with the indolent cutaneous T-cell LPD suggest the possibility of a response to an unknown antigen.
NK-cell enteropathy
NK-cell enteropathy is an indolent proliferation of NKcells in the GI tract, also designated lymphomatoid gastropathy when limited to the stomach. [101] [102] [103] Patients are either asymptomatic or have non-specific GI symptoms and no history of celiac disease, inflammatory bowel disease or malabsorption. 102 A subset of patients in one study had a prior history of gastric carcinoma and frequent H.pylori infection. 103 Endoscopic findings include superficial ulceration with surrounding hemorrhage and edema, with some patients showing multifocal involvement of the stomach, small bowel and colon. Luminal masses have not been described and imaging studies show no evidence of lymphadenopathy or organomegaly. 102, 103 The biopsies show expansion of the lamina propria by an atypical lymphoid infiltrate of intermediate cells with irregular nuclei, moderate pale to eosinophilic cytoplasm, seen in a mixed inflammatory background. Ulceration of the overlying mucosa is present but epitheliotropism as seen in EATL is not identified (Figure 4D-F) . The atypical cells are positive for cytoplasmic CD3, CD7, CD56 and cytotoxic markers but negative for EBV. Molecular analysis for clonal TCRG is negative and cytogenetic studies have not been successful due to scant diagnostic material. 102, 103 The etiology of NK-cell enteropathy remains unknown. NK-cells are present in the GI tract as part of the innate immune system. 104 Native gut NK-cells produce cytokines but have poor cytotoxic activity, unless they are primed by exposure to antigens. 105 The atypical NK-cell infiltrates described above express cytotoxic markers, suggesting an activated phenotype. Nine out of 10 patients with lymphomatoid gastropathy were positive for H.pylori, but with a high prevalence of this infection in the Japanese population, and regression of lesions in some patients without antibiotic therapy, the significance of this finding is unknown. 103 Additional studies (cytogenetics, array CGH, mutation analyses) will help determine if these lesions are clonal expansions or an atypical reactive process.
NK-cell enteropathy/lymphomatoid gastropathy has a protracted but indolent clinical course with no involvement outside the GI tract or progression to an aggressive NK-cell neoplasm. The majority of cases reported in the literature had persistent lesions, some even after therapy, while a subset showed spontaneous regression. All patients were clinically stable and asymptomatic after a long follow up. Based on the indolent nature of this entity, observation without treatment is recommended. 102, 103 Recognition of this unique entity and correlation with clinical features and endoscopic findings is critical to prevent a misdiagnosis of lymphoma.
Breast implant-associated anaplastic large-cell lymphoma
Non-Hodgkin lymphomas involving the breast are predominantly of B-cell type while T-cell lymphomas are rare. However, ALCL, ALK-negative associated with breast implants were first reported in 1997. 106 In 2011, the US Food and Drug Administration reported 60 documented cases of breast implant-associated ALCL. The real incidence of this entity may be higher, as seroma effusions have been inconsistently submitted for microscopic examination. 107 In a recent review, no statistical difference was identified between indication for breast-implants (cosmetic vs. reconstructive surgery), laterality and type of implant (saline vs. silicone). 108 The median time to diagnosis of ALCL after implantation was nine years. Patients most often presented with a peri-implant effusion (seroma) or less commonly with a mass adjacent to the effusion. The majority of the patients underwent explantation, drainage of the effusion and capsular excision. Tumor cells were seen in the effusion fluid and capsule, without extra-capsular extension (cases with effusion) or forming distinct aggregates outside the capsule (cases with tumor mass). The cells had anaplastic morphology, including distinctive hallmark cells, and were strongly CD30-positive and ALKnegative ( Figure 4G-I ). Molecular analysis showed clonal TCRG rearrangements in 28 of 29 cases tested. 108 Clinical management was variable and ranged from capsulectomy, mastectomy, radiotherapy, chemotherapy and autologous stem cell transplantation. While median follow-up periods are short (2 years), 93% of patients without a mass had a complete remission compared to 72% of patients with a mass. Interestingly, adjuvant chemotherapy did not significantly improve clinical outcome and remission rates were much better than systemic ALK-negative ALCL. 108 If there is no capsular invasion, conservative management with implant and capsular removal is favored.
Conclusions
In this review we have discussed a group of lymphoproliferative disorders that have unique features and are associated with an indolent behavior. They can be broadly divided into two groups. The first group includes MGUS, MBL, FLIS/FLBUS and MCLIS/MCLBUS. These are clonal Early events in lymphomagenesis haematologica | 2014; 99 (9) proliferations that share genetic and molecular alterations with well-characterized lymphoid neoplasms, multiple myeloma, CLL/SLL, follicular lymphoma and mantle cell lymphoma. However, these "early forms" are often diagnosed incidentally with only a small fraction progressing to symptomatic disease. Studying these precursor lesions has provided insight into the biology of lymphomagenesis in a manner analogous to the "adenoma-carcinoma" pathways in epithelial malignancies. The use of highly sensitive ancillary and screening tests has led to an increase in the diagnosis of these entities and the emphasis over the past few years has been to identify factors that may play a role in progression, to better assess patient risk, and provide a rationale for patient management. A second group of clonal lymphoid proliferations resemble lymphoma, but are associated with an indolent clinical course and excellent prognosis. They appear to lack the molecular alterations leading to autonomous growth and clinically malignant behavior. However, due to the clonal nature of the proliferation, and the sometimes atypical clinical or pathological features, they have been diagnosed as "lymphomas". They may represent an exaggerated response to antigen, clonal but self-limited. This scenario seems most likely for the pediatric variants of nodal FL and MZL. For some conditions, such as breast-implant associated ALCL, the benign clinical behavior may be related to the anatomically confined nature of the proliferation within the capsule surrounding the implant. If the cells escape this compartment, the risk for progression is much greater. Further studies are required to understand the molecular aberrations that lead to autonomous growth. Integration of clinical and pathological data and awareness of these entities is crucial to prevent misdiagnosis and subsequent inappropriate therapy. 
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